Author name: Leonardo Arias

While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and gene therapies, and antibody-drug conjugates, will enjoy exemptions that waive or greatly reduce the levies.

BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.

Los CFD han facilitado el acceso de los operadores a los mercados financieros globales sin tener que invertir en los activos subyacentes. Por ejemplo, puedes especular sobre el precio del oro sin comprarlo ni poseerlo.   Dependiendo del instrumento financiero que le interese, una cuenta de CF …

La mayor parte del texto que circula en internet ha sido tocado por algún modelo de lenguaje: redactado, resumido, corregido o expandido con IA. Y en respuesta a eso, ha surgido toda una rama de la lingüística computacional dedicada a detectar exactamente eso. El resultado es una …

After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie.

Clinicians’ use of an AI scribe was associated with 13 fewer minutes each day inside electronic health records and 16 fewer minutes on documenting patient care, according to the research published in JAMA.

Community Health Systems completed the divestiture of Crestwood Medical Center this week as the for-profit operator continues paying down its debt.

View Point sells tumor tissue localization devices that could complement Merit’s existing presence in the sector.

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since January.

With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore regulatory clarity” for rare disease therapies. Experts on a BioSpace panel last week also acknowledged the challenges faced by a more stringent